Signals
10Thyroid cancer targeted therapy expands across differentiated, medullary, and anaplastic subtypes
RET inhibitor maturity, NTRK fusion-targeted use, BRAF V600E and MEK combinations in anaplastic disease, and emerging mechanism programs are restructuring thyroid cancer therapy.
Lung cancer screening pathway integration matures
Low-dose CT screening adoption growth, AI-assisted nodule management, blood-based biomarker integration, and primary-care pathway formalisation are restructuring lung cancer screening.
Soft tissue sarcoma therapy widens around fusion-defined biomarkers
NTRK inhibitor cross-tumour use, GIST line-of-therapy expansion, and emerging mechanism-targeted programs are reshaping soft tissue sarcoma management.
Cholangiocarcinoma targeted therapy widens past chemotherapy
FGFR2 inhibitor maturity, IDH1 inhibitor use, HER2-targeted therapy entry, and IO combinations are restructuring biliary tract cancer management.
Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Colorectal cancer third-line and KRAS-targeted options widen
KRAS G12C-targeted programs, fruquintinib third-line use, and trastuzumab deruxtecan in HER2-amplified colorectal are restructuring late-line colorectal cancer.
Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
KRAS G12C resistance patterns are reshaping second-line NSCLC sequencing
Resistance mechanisms emerging from sotorasib and adagrasib post-progression sampling are converging on a finite set of pathways. The implications for second-line decision-making and combination design are starting to land in clinic.
TROP2 ADC class read-throughs from Q1 2026 readouts
The TROP2 antibody-drug conjugate class has multiple late-stage assets reading out in overlapping breast cancer and NSCLC populations. Q1 2026 readouts have started to differentiate the class on toxicity profile and biomarker dependency rather than on bulk efficacy.
Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
Snapshots
3Thyroid cancer therapy reference (2026)
Reference snapshot of thyroid cancer therapy across differentiated, medullary, and anaplastic subtypes.
Cholangiocarcinoma therapy reference (2026)
Reference snapshot of cholangiocarcinoma therapy across resectable and advanced disease and biomarker-defined targeted tiers.
Adult diffuse glioma therapy reference (2026)
Reference snapshot of adult diffuse glioma therapy across IDH-mutant grade 2/3 disease, glioblastoma first-line, and recurrent disease.
Explained
2ctDNA-guided treatment decisions are entering routine oncology care
Circulating tumour DNA testing has moved from research-grade tool to a routine decision aid in several oncology indications. The pathways from blood draw to clinical decision are now described well enough to plan around, even though reimbursement remains uneven.
Why 'tumor-agnostic' approvals are reshaping reimbursement reviews
When a drug is approved for a molecular target across tumor types rather than for one cancer, the HTA review framework has to evaluate efficacy across heterogeneous indications with different unmet needs, comparators, and standard-of-care benchmarks. That has practical consequences for access timelines.